Literature DB >> 22836249

NADPH oxidase-4 maintains neuropathic pain after peripheral nerve injury.

Wiebke Kallenborn-Gerhardt1, Katrin Schröder, Domenico Del Turco, Ruirui Lu, Katharina Kynast, Judith Kosowski, Ellen Niederberger, Ajay M Shah, Ralf P Brandes, Gerd Geisslinger, Achim Schmidtko.   

Abstract

Reactive oxygen species (ROS) contribute to sensitization of pain pathways during neuropathic pain, but little is known about the primary sources of ROS production and how ROS mediate pain sensitization. Here, we show that the NADPH oxidase isoform Nox4, a major ROS source in somatic cells, is expressed in a subset of nonpeptidergic nociceptors and myelinated dorsal root ganglia neurons. Mice lacking Nox4 demonstrated a substantially reduced late-phase neuropathic pain behavior after peripheral nerve injury. The loss of Nox4 markedly attenuated injury-induced ROS production and dysmyelination processes of peripheral nerves. Moreover, persisting neuropathic pain behavior was inhibited after tamoxifen-induced deletion of Nox4 in adult transgenic mice. Our results suggest that Nox4 essentially contributes to nociceptive processing in neuropathic pain states. Accordingly, inhibition of Nox4 may provide a novel therapeutic modality for the treatment of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836249      PMCID: PMC6703722          DOI: 10.1523/JNEUROSCI.6227-11.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  34 in total

Review 1.  New insights on NOX enzymes in the central nervous system.

Authors:  Zeynab Nayernia; Vincent Jaquet; Karl-Heinz Krause
Journal:  Antioxid Redox Signal       Date:  2014-01-16       Impact factor: 8.401

Review 2.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 3.  NADPH oxidases in oxidant production by microglia: activating receptors, pharmacology and association with disease.

Authors:  J Haslund-Vinding; G McBean; V Jaquet; F Vilhardt
Journal:  Br J Pharmacol       Date:  2016-02-26       Impact factor: 8.739

Review 4.  Role of reactive oxygen species and TRP channels in the cough reflex.

Authors:  Thomas E Taylor-Clark
Journal:  Cell Calcium       Date:  2016-03-14       Impact factor: 6.817

5.  Activation of TRPM2 and TRPV1 Channels in Dorsal Root Ganglion by NADPH Oxidase and Protein Kinase C Molecular Pathways: a Patch Clamp Study.

Authors:  Mustafa Nazıroğlu
Journal:  J Mol Neurosci       Date:  2017-01-17       Impact factor: 3.444

Review 6.  Nitroxidative Signaling Mechanisms in Pathological Pain.

Authors:  Peter M Grace; Andrew D Gaudet; Vasiliki Staikopoulos; Steven F Maier; Mark R Hutchinson; Daniela Salvemini; Linda R Watkins
Journal:  Trends Neurosci       Date:  2016-11-12       Impact factor: 13.837

Review 7.  Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement.

Authors:  Sebastian Altenhöfer; Kim A Radermacher; Pamela W M Kleikers; Kirstin Wingler; Harald H H W Schmidt
Journal:  Antioxid Redox Signal       Date:  2014-02-26       Impact factor: 8.401

Review 8.  Schwann cell interactions with axons and microvessels in diabetic neuropathy.

Authors:  Nádia P Gonçalves; Christian B Vægter; Henning Andersen; Leif Østergaard; Nigel A Calcutt; Troels S Jensen
Journal:  Nat Rev Neurol       Date:  2017-01-30       Impact factor: 42.937

9.  Reactive species modify NaV1.8 channels and affect action potentials in murine dorsal root ganglion neurons.

Authors:  Martin Schink; Enrico Leipold; Jana Schirmeyer; Roland Schönherr; Toshinori Hoshi; Stefan H Heinemann
Journal:  Pflugers Arch       Date:  2015-09-17       Impact factor: 3.657

10.  NADPH-oxidase 2 activation promotes opioid-induced antinociceptive tolerance in mice.

Authors:  T Doyle; E Esposito; L Bryant; S Cuzzocrea; D Salvemini
Journal:  Neuroscience       Date:  2013-02-27       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.